Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

3. fázisTaking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuyang, Fuzhou, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hohhot, Jinan, Kunming, Luoyang, Luzhou, Nanchang, Nanning, Nanyang, Qingdao, Shanghai, Shenyang, Tai’an, Taizhou, Tianjin, Weifang, Weihui, Wenzhou, Xi’an, Zhengzhou, Zhuzhou
Életkor
18 év and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Beijing, Hangzhou, Jinan, Linhai, Linyi, Nanchang, Nanning, Xiamen
Életkor
18 év and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
1/2. fázisTaking people
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Where
Hangzhou
Életkor
18 év and over
People
120 worldwide
Run by
Betta Pharmaceuticals Co., Ltd.
See details and how to joinNCT07435038
No phaseTaking people
Precision Navigation to Improve Community Cancer Screening Participation
Where
Huaihua, Shaoyang, Yongzhou
Életkor
45 év to 74 év
People
1500
Run by
Hunan Cancer Hospital
See details and how to joinNCT07676383
No phaseTaking people
AI-Personalized Discharge Education for Patients After Lung Cancer Surgery
Where
Siping
Életkor
18 év to 80 év
People
156
Run by
Xiamen University
See details and how to joinNCT07827183
2. fázisNot yet taking people in Kína
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Guangzhou
Életkor
18 év to 75 év
People
36
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07827261
3. fázisTaking people
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Where
Beijing, Shanghai
Életkor
18 év to 99 év
People
400 worldwide
Run by
Amgen
See details and how to joinNCT07778316
2. fázisNot yet taking people in Kína
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
Where
Guangzhou
Életkor
18 év to 75 év
People
138
Run by
Sun Yat-sen University
See details and how to joinNCT07824856
No phaseTaking people
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Where
Foshan, Guangzhou, Shantou, Zhongshan
Életkor
18 év and over
People
180
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT05457049
1/2. fázisTaking people
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Where
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lishui, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
Életkor
18 év and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00
1/2. fázisTaking people
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Where
Bengbu, Changsha
Életkor
18 év and over
People
60
Run by
Heronova Pharmaceuticals
See details and how to joinNCT06873555
No phaseTaking people
SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
Where
Hangzhou
Életkor
18 év and over
People
15
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07823855
2. fázisTaking people
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Where
Changsha, Hangzhou, Jinan
Életkor
18 év and over
People
40
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07061535
2. fázisNot yet taking people in Kína
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
Where
Guangzhou
Életkor
18 év and over
People
47
Run by
Shaodong Hong
See details and how to joinNCT07819591
No phaseNot yet taking people in Kína
Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
Where
Beijing, Shenzhen, Taiyuan
Életkor
18 év to 80 év
People
160
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07819669
No phaseTaking people
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
Where
Changsha
Életkor
18 év and over
People
600
Run by
Central South University
See details and how to joinNCT07820423
1/2. fázisTaking people
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Beijing, Shanghai
Életkor
18 év and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00
2. fázisNot yet taking people in Kína
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
Where
Lianyungang
Életkor
18 év to 80 év
People
61
Run by
The First People's Hospital of Lianyungang
See details and how to joinNCT07818304
2. fázisTaking people
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Where
Hangzhou
Életkor
18 év to 75 év
People
38
Run by
Jin Ying
See details and how to joinNCT06483282
2. fázisTaking people
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Where
Shanghai
Életkor
18 év to 80 év
People
27
Run by
Fudan University
See details and how to joinNCT06738160
No phaseTaking people
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Where
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjing, Wuhan, Wuxi, Yangzhou, Zhengzhou
Életkor
18 év and over
People
200
Run by
AstraZeneca
See details and how to joinNCT07161388
2. fázisTaking people
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
Where
Yantai
Életkor
18 év to 75 év
People
20
Run by
Yantai Yuhuangding Hospital
See details and how to joinNCT07815223
1. fázisNot yet taking people in Kína
Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
Where
Wuhan
Életkor
18 év to 75 év
People
8
Run by
Yong He
See details and how to joinNCT07815951
3. fázisTaking people
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Where
Shanghai
Életkor
18 év to 75 év
People
759
Run by
Fudan University
See details and how to joinNCT07554846
3. fázisTaking people
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Where
Jinan
Életkor
18 év to 75 év
People
418
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07640789